Demographic and clinical characteristics of the 115 patients
| Characteristic | Ciclosporin (n=60) | Infliximab (n=55) | p Value |
|---|---|---|---|
| Female gender, n (%) | 28 (47) | 27 (49) | 0.79 |
| Median age, years (IQR) | 39 (26–50) | 36 (26–51) | 0.48 |
| Median disease duration, years (IQR) | 2.5 (0.5–7.3) | 0.8 (0.1–4.4) | 0.07 |
| First attack of UC, n (%) | 10 (17) | 16 (29) | 0.11 |
| Disease location E3,18 n (%) | 34 (57) | 31 (56) | 0.93 |
| Patient naive to azathioprine, n (%) | 56 (93) | 51 (93) | 0.90 |
| Median intravenous. steroid duration, days (IQR) | 7 (6–9)* | 8 (6–9)† | 0.72 |
| Median Lichtiger score (IQR) | 12 (11–13) | 13 (12–14) | 0.004 |
| Median Mayo disease activity index (IQR) | 10 (10–11) | 11 (10–11) | 0.26 |
| Mayo endoscopic subscore=3, n (%) | 57 (95) | 53 (96) | 0.73 |
| Median CRP (mg/L, IQR) | 30 (16–66)‡ | 46 (28–73)† | 0.044 |
| Median albumin (g/L, IQR) | 28 (24–32)§ | 27 (23–33)¶ | 0.55 |
*n=59.
†n=54.
‡n=57.
§n=56.
¶n=49.
UC location according to the Montreal classification18 (E1: n=0).
CRP, C reactive protein.